<td class= Dadun
   (New user)
Help  | Contact  |  Castellano English  

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Oncología > Inmunoterapia > DA - CIMA - Oncología - Inmunoterapia - Artículos de Revista >

Anemia in chronic lymphatic leukemia: is erythropoietin the solution?
Authors: Ruiz-de-Gaona, E. (Estefanía)
Rifon, J. (Jose)
Perez-Calvo, J. (Javier)
Bendandi, M. (Maurizio)
Iglesias, R. (Rafael)
Panizo, C. (Carlos)
Keywords: Anemia
Lymphoproliferative syndrome
Chronic lymphocytic leukemia
Issue Date: 2007
Publisher: Universidad de Navarra
Publisher version:
ISSN: 0556-6177
Citation: de Gaona ER, Rifon J, Perez-Calvo J, Bendandi M, Iglesias R, Panizo C. Anemia in chronic lymphatic leukemia: is erythropoietin the solution? Rev Med Univ Navarra 2007 Jan-Mar;51(1):3-10.
Anemia is a common complication in the clinical course of chronic lymphocytic leukemia. Low hemoglobin levels both correlate with an adverse prognosis and adversely affect the quality of life of chronic lymphocytic leukemia patients. Different physiopathological phenomena may lead to anemia: marrow infi ltration, hypersplenism, immune hemolysis or toxicity of chemotherapy. Treatment with human recombinant erythropoietic agents has been shown to be effective for anemia associated with different lymphoproliferative syndromes. This paper analyses the available evidence on erythropoietic agent treatment for chronic lymphocytic leukemia associated anemia. The comparative effect of different dosage schemes, the role of possible response-prediction factors such as the endogenous erythropoietin level and the results achieved using darbopoietin alpha are reviewed.
Permanent link:
Appears in Collections:DA - CIMA - Oncología - Inmunoterapia - Artículos de Revista
DA - CUN - Hematología y Hemoterapia - Artículos de revista
DA - CUN - Área de Terapia Celular - Artículos de revista
DA - Medicina - Hematología - Artículos de revista

Files in This Item:

There are no files associated with this item.

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.